In the third quarter of 2025, companies worth less than $500 million accounted for 57% of biopharma acquisitions by count, at a median deal value of $303 million. These are the transactions that decide whether a founder's decade of work clears the bar or dies on the runway, and almost none of them require a bulge bracket. Yet the reflex in life science investment banking is to reach for a Goldman Sachs or a Morgan Stanley the moment a term sheet lands, on the theory that a famous name on the fairness opinion buys credibility with the board. At $200 million of market value that theory is mostly wrong, and the 2024 to mid-2026 deal record shows why.
The credibility reflex
The instinct is understandable. A board approving a sale faces shareholder litigation if the price looks low, and a recognizable advisor on the fairness opinion feels like insurance. The trouble is that the insurance is mispriced. Healthcare banking league tables, the source most directors lean on, are built from the top of the deal-size distribution: a bank that serves as third co-advisor on a $15 billion merger earns the same deal-count credit as the exclusive seller's advisor on a $150 million acquisition. Centerview Partners tops the biopharma rankings by deal value because it works the largest transactions, not because it is the most active firm in the $100-300 million band where most small-cap deals close. Read that way, the table tells a board almost nothing about who will run its own process well. The right question at $200 million is not which bank is most prestigious. It is which operational lever the deal most needs, and which firm pulls that lever hardest.
Four criteria, not a brand
Strip away the logo and four things decide whether an advisor earns its fee on a sub-$500 million deal. The first is relationship leverage: whether a senior banker who knows your board will work the deal, or whether a famous firm will staff it with juniors. A named partner at Centerview will often not personally run a $200 million sell-side; a sector boutique's founder will. The second is sector depth, the gap between a generalist who covered software last quarter and a banker who has priced dozens of oncology assets and knows which acquirer's medical team is quietly enthusiastic. The third is allocator network: at $200 million the ability to place a $50-100 million private placement matters as much as M&A execution, and such placements, known as PIPEs, were 87% of biotech follow-ons in 2025, at an average size of $58 million. The fourth is conflict cleanliness, which since two 2024 Delaware rulings is no longer a soft preference but a litigation exposure. Rank a prospective advisor on those four, weight them to the deal in front of you, and the brand question answers itself.
Where the boutique wins: early licensing
For early licensing and asset sales the specialist boutique holds a structural edge no bulge bracket can buy. Centerview advised on about half of all biopharma acquisitions worth $200 million or more across 2023 and 2024, and on 19 of the 23 biotech deals worth $1 billion or more in 2023; its co-president, Eric Tokat, has personally advised more than 100 healthcare transactions. The firm's grip on biotech boards is so complete that practitioners reduce it to a single line: no board has ever regretted hiring Centerview. Leerink Partners, the only standalone healthcare investment bank left in America after its 2023 buyout from the wreckage of Silicon Valley Bank, commands the deepest sector research and investor access. Evercore, whose advisory fees more than doubled to $807 million in early 2026, has climbed into the same tier. Below them sit the licensing specialists who own the earliest deals: Locust Walk, which has closed more than 20 company or asset sales, advised Checkpoint Therapeutics on its sale to Sun Pharma for up to $416 million; Back Bay Life Science Advisors structured the license of Centrexion's non-opioid pain asset to Eli Lilly for $47.5 million upfront and up to $950 million in milestones. What these firms run is a structured process, targeted outreach to 6-15 qualified counterparties rather than a broad auction, which is the right design for a Phase 1 or Phase 2 asset whose unreleased data a wide buyer pool should not see.
Where the bulge wins: defensive and cross-border M&A
The honest case for the bulge bracket lives in defensive and cross-border situations. A $200 million company facing a $350 million unsolicited bid needs an advisor who can credibly threaten to source a competing offer, which takes live relationships with large-cap acquirers and the syndicate muscle to raise equity fast. That is the bulge bracket's home turf, though the elite boutiques have learned to play it: PJT Partners runs an active activism-defense practice, having fended off campaigns from Carl Icahn and Corvex, and advised on the $28.3 billion Horizon Therapeutics buyout. Cross-border is the other case. For a US biotech selling into a competitive process to a major European or Japanese acquirer above $500 million, a bank with offices in Tokyo, London and Frankfurt runs parallel buyer outreach and foreign regulatory review in a way a 30-person boutique cannot. And whichever firm a board picks, the advisor's job ends at the letter of intent; the 90 days after, where most of the value is won or lost, are a separate discipline the same league-table reflex tends to neglect.
The capital structure question
The third decision point is the one boards weigh least and need most: how to fund the company without selling it. Here the relevant advisors are rarely bulge brackets at all. Royalty and revenue-based financings raised more than $3.4 billion in the first half of 2025, and the counterparties are specialists. Royalty Pharma, which holds more than 60% of the global royalty market, committed up to $2 billion to Revolution Medicines in June 2025, $1.25 billion of synthetic royalty plus $750 million of secured debt. Term lenders run a parallel track: Pharmakon Advisors, manager of the BioPharma Credit funds, has committed over $13 billion across 78 transactions, including a $200 million senior secured loan to UroGen Pharma in early 2026. Sixth Street put $500 million into Arrowhead Pharmaceuticals and another $500 million into Beam Therapeutics, a deal on which Beam's chief financial officer, Sravan Emany, said the structure gave the company "long-term, non-dilutive capital" to fund a launch without diluting the pipeline. The convertible market set a record $7.37 billion in 2025, though it stays open mainly to commercial-stage names with revenue to service the coupon. The lesson repeats: at this size the right partner is the one with the deepest book in the specific instrument, not the largest balance sheet overall.
What life science investment banking costs
Fees are where the brand premium turns literal. At the $100-500 million deal size a boutique or elite boutique typically charges a 1-2% success fee, against the 0.5-1.0% a bulge bracket charges on the same deal; the gap narrows as deals get larger. But the boutique often recovers its premium, and more, through sharper process management and a higher final price, which is the only number a seller should weigh. The mandate record bears out the specialization. One healthcare banker with three years in biotech coverage ranked the field bluntly: Centerview alone at the top; then JPMorgan, Evercore, Morgan Stanley and Lazard; then Bank of America, PJT, Goldman and Citi; then Jefferies, Leerink and the sector shops, with everyone else "working scraps and very small cap." Read against the deal flow, that ranking is a map of who shows up at each size, which is the question a $200 million board should ask in place of who is most famous.
The conflict question, now a legal one
Conflict cleanliness used to be a matter of taste. Two Delaware rulings in the spring of 2024 made it a matter of law. In City of Sarasota Firefighters' Pension Fund v. Inovalon Holdings, the state Supreme Court reversed a dismissal and held that a proxy which failed to disclose its financial advisors' concurrent and prior work for the buyer and its co-investors had left shareholders uninformed, stripping the deal of business-judgment protection; In re Match Group reinforced the standard. The practical effect is that a board relying on a full-service bank, which may carry lending or trading ties to the acquirer, now has to run and disclose far more thorough conflict checks than before. Advisory-only firms with no trading desk or principal investments carry structurally less of this risk. The confidentiality risk is just as real: in December 2025 the SEC and federal prosecutors charged a former Lazard healthcare banker with leaking inside information on nine biopharma deals between 2020 and 2023, a reminder that a process is only as clean as the people who run it. The board's task is concrete: require each prospective advisor to disclose, in writing, every engagement with likely buyers and to describe its conflict-clearance procedure before the mandate is signed.
The decision framework: seven moves
Seven moves separate the boards that pick the right advisor from the ones that pick the famous one.
One. Define the transaction before you interview advisors. Early licensing, a full sale, a defensive response and a financing each reward a different firm; do not hire one advisor for a need you have not named.
Two. Weight the four criteria to that transaction. Relationship leverage and sector depth dominate a licensing deal; allocator network dominates a financing; cross-border reach and syndicate muscle dominate a contested sale.
Three. Insist that the senior banker who pitches is the one who works the deal. Get the staffing in writing. A famous firm that assigns juniors is worse than a boutique whose founder answers the phone.
Four. Price the fee against the outcome, not the rate card. A 1-2% boutique fee that delivers a higher clearing price beats a 0.5% bulge fee on a mishandled process.
Five. Run the conflict check before the mandate. Require written disclosure of every engagement with likely buyers, and a description of the firm's clearance procedure. After Inovalon this protects the board as much as the deal.
Six. Match the financing advisor to the instrument. A royalty deal, a term loan and a convertible are three markets with three specialist counterparties; the M&A advisor is rarely the right one for any of them.
Seven. Reserve the bulge bracket for the cases that need it. A genuinely cross-border auction or a hostile defense is where its firepower earns the premium. Everywhere else the premium is a habit, not a requirement.
The bulge case is real. It is also the exception.
None of this means the bulge bracket is never the answer. Cross-border firepower is real; so is the syndicate reach that mounts a credible defense against an unsolicited bid, and the distribution that places an offering above $200 million. A board that expects a 20-buyer auction, or that needs equity bridge financing alongside the M&A advice, has a defensible reason to pay for the balance sheet behind the name.
But those are the exceptions, and most $200 million biotechs are not living in them. The common case is a single asset, a handful of logical buyers and a financing a specialist places better than a generalist. For that company the famous logo buys board comfort and little else, while a sector boutique buys a senior banker, a cleaner conflict profile and, often, a higher price. The discipline is to choose on the four criteria the deal presents, and to spend the brand premium only where it pays for itself.